These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38733973)

  • 1. Response to Antibiotic Treatment of Bacterial Vaginosis Predicts the Effectiveness of LACTIN-V (Lactobacillus crispatus CTV-05) in the Prevention of Recurrent Disease.
    Hemmerling A; Wierzbicki MR; Armstrong E; Cohen CR
    Sex Transm Dis; 2024 Jun; 51(6):437-440. PubMed ID: 38733973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis.
    Cohen CR; Wierzbicki MR; French AL; Morris S; Newmann S; Reno H; Green L; Miller S; Powell J; Parks T; Hemmerling A
    N Engl J Med; 2020 May; 382(20):1906-1915. PubMed ID: 32402161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of bacterial vaginosis-associated bacteria and sexual intercourse on vaginal colonization with the probiotic Lactobacillus crispatus CTV-05.
    Ngugi BM; Hemmerling A; Bukusi EA; Kikuvi G; Gikunju J; Shiboski S; Fredricks DN; Cohen CR
    Sex Transm Dis; 2011 Nov; 38(11):1020-7. PubMed ID: 21992977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment: results from a randomised, placebo-controlled trial.
    Armstrong E; Hemmerling A; Miller S; Burke KE; Newmann SJ; Morris SR; Reno H; Huibner S; Kulikova M; Nagelkerke N; Coburn B; Cohen CR; Kaul R
    Lancet Microbe; 2022 Jun; 3(6):e435-e442. PubMed ID: 35659905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaginal Lactobacillus crispatus persistence following application of a live biotherapeutic product: colonization phenotypes and genital immune impact.
    Armstrong E; Hemmerling A; Miller S; Huibner S; Kulikova M; Crawford E; Castañeda GR; Coburn B; Cohen CR; Kaul R
    Microbiome; 2024 Jun; 12(1):110. PubMed ID: 38907268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaginal fungi are associated with treatment-induced shifts in the vaginal microbiota and with a distinct genital immune profile.
    Armstrong E; Hemmerling A; Miller S; Huibner S; Kulikova M; Liu R; Crawford E; Castañeda GR; Coburn B; Cohen CR; Kaul R
    Microbiol Spectr; 2024 Aug; 12(8):e0350123. PubMed ID: 38912808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Connecting the Dots: Translating the Vaginal Microbiome Into a Drug.
    Lagenaur LA; Hemmerling A; Chiu C; Miller S; Lee PP; Cohen CR; Parks TP
    J Infect Dis; 2021 Jun; 223(12 Suppl 2):S296-S306. PubMed ID: 33330916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection.
    Stapleton AE; Au-Yeung M; Hooton TM; Fredricks DN; Roberts PL; Czaja CA; Yarova-Yarovaya Y; Fiedler T; Cox M; Stamm WE
    Clin Infect Dis; 2011 May; 52(10):1212-7. PubMed ID: 21498386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of vaginally administered lyophilized Lactobacillus crispatus IP 174178 in the prevention of bacterial vaginosis recurrence.
    Bohbot JM; Daraï E; Bretelle F; Brami G; Daniel C; Cardot JM
    J Gynecol Obstet Hum Reprod; 2018 Feb; 47(2):81-86. PubMed ID: 29196153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study.
    Larsson PG; Stray-Pedersen B; Ryttig KR; Larsen S
    BMC Womens Health; 2008 Jan; 8():3. PubMed ID: 18197974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaginal colonisation by probiotic lactobacilli and clinical outcome in women conventionally treated for bacterial vaginosis and yeast infection.
    Pendharkar S; Brandsborg E; Hammarström L; Marcotte H; Larsson PG
    BMC Infect Dis; 2015 Jul; 15():255. PubMed ID: 26137971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orally administrated
    Qi F; Fan S; Fang C; Ge L; Lyu J; Huang Z; Zhao S; Zou Y; Huang L; Liu X; Liang Y; Zhang Y; Zhong Y; Zhang H; Xiao L; Zhang X
    Front Immunol; 2023; 14():1125239. PubMed ID: 37575226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis.
    Hemmerling A; Harrison W; Schroeder A; Park J; Korn A; Shiboski S; Foster-Rosales A; Cohen CR
    Sex Transm Dis; 2010 Dec; 37(12):745-50. PubMed ID: 20644497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The restoration of the vaginal microbiota after treatment for bacterial vaginosis with metronidazole or probiotics.
    Ling Z; Liu X; Chen W; Luo Y; Yuan L; Xia Y; Nelson KE; Huang S; Zhang S; Wang Y; Yuan J; Li L; Xiang C
    Microb Ecol; 2013 Apr; 65(3):773-80. PubMed ID: 23250116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An exploratory pilot study evaluating the supplementation of standard antibiotic therapy with probiotic lactobacilli in south African women with bacterial vaginosis.
    Marcotte H; Larsson PG; Andersen KK; Zuo F; Mikkelsen LS; Brandsborg E; Gray G; Laher F; Otwombe K
    BMC Infect Dis; 2019 Sep; 19(1):824. PubMed ID: 31533663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial.
    Bradshaw CS; Pirotta M; De Guingand D; Hocking JS; Morton AN; Garland SM; Fehler G; Morrow A; Walker S; Vodstrcil LA; Fairley CK
    PLoS One; 2012; 7(4):e34540. PubMed ID: 22509319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of oral and vaginal metronidazole for treatment of bacterial vaginosis in pregnancy: impact on fastidious bacteria.
    Mitchell CM; Hitti JE; Agnew KJ; Fredricks DN
    BMC Infect Dis; 2009 Jun; 9():89. PubMed ID: 19515236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supplementation of standard antibiotic therapy with oral probiotics for bacterial vaginosis and aerobic vaginitis: a randomised, double-blind, placebo-controlled trial.
    Heczko PB; Tomusiak A; Adamski P; Jakimiuk AJ; Stefański G; Mikołajczyk-Cichońska A; Suda-Szczurek M; Strus M
    BMC Womens Health; 2015 Dec; 15():115. PubMed ID: 26635090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing the regulatory framework in South Africa - a single-blind randomized pilot trial of commercial probiotic supplementation to standard therapy in women with bacterial vaginosis.
    Happel AU; Singh R; Mitchev N; Mlisana K; Jaspan HB; Barnabas SL; Passmore JS
    BMC Infect Dis; 2020 Jul; 20(1):491. PubMed ID: 32650729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of biofilms in bacterial vaginosis by an amphoteric tenside pessary-clinical study and microbiota analysis.
    Gottschick C; Deng ZL; Vital M; Masur C; Abels C; Pieper DH; Rohde M; Mendling W; Wagner-Döbler I
    Microbiome; 2017 Sep; 5(1):119. PubMed ID: 28903767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.